Marinus Pharmaceuticals, Inc. - Special Call Transcript
Thank you, everyone. So this morning, we're going to have our newly appointed Chief Medical Officer, Dr. Joseph Hulihan, take us through the use of Ganaxolone IV in refractory status epilepticus.
Specifically, he's going to speak to the new Phase II data that was presented here this weekend at AES, as well as our plans for our Phase III clinical trial.
Joe will then turn the presentation over to TJ Lyons. TJ is our VP of Business Development and Commercial Opportunities. And TJ will take us through the market opportunity for status epilepticus and refractory status epilepticus.
After their presentations, I ask that you hold all of your questions until the end of their presentations, at which time they will be available for the Q&A and joining them will also be Dr. Michael Rogawski from UC Davis as well as Dr. Eugene Ramsay from the Ochsner Comprehensive Epilepsy Center, who is also an investigator in our Phase II clinical study.
And quickly, before we begin
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
